BIOMEDICAL ADVANCED RESEARCH
AND DEVELOPMENT AUTHORITY (BARDA)
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.
The mission of the Biomedical Advanced Research and Development Authority (BARDA) is to develop and procure medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. Specifically, BARDA supports the advanced development and procurement of drugs, vaccines and other products that are considered priorities for national health security through its programmatic initiatives.
BARDA supports a number of core services to assist the production of required products, in a manner that is timely, reliable and cost effective.
The Pandemic and All Hazards Preparedness Act (PAHPA) established BARDA as the focal point within HHS for the advanced development and acquisition of medical countermeasures to protect the American civilian population against CBRN and naturally occurring threats to public health.
Emerging Infectious Diseases rutrum viverra nibh, quis placerat felis bibendum quis. Vivamus lobortis facilisis velit faucibus maximus. Nulla tempus urna mi. Nam placerat semper euismod. Vivamus cursus est quis pulvinar pulvinar.
BARDA's Strategic Science and Technology Division helps bring innovation to our programs. The innovation programs identify and support the advancement of platform technologies that enhance capabilities for the development and manufacturing of medical countermeasures that focus on biodefense, pandemic influenza and other emerging infectious diseases.
Congress seeks to improve our Nation's emergency preparedness with Project BioShield, which provides the government with the ability to develop, acquire, stockpile, and make available the medical countermeasures needed to protect the U.S. population against a public health threat.
BARDA funding and acquisitions bridge the "valley of death" characterizing the late stages of product development. BARDA's support ensures continuity of funding for medical countermeasures developed by industry or emerging from the basic research and preclinical development activities sponsored by the National Institutes of Health (NIH). In procuring medical countermeasures for the Strategic National Stockpile, BARDA enhances the capabilities of the Centers for Disease Control and Prevention (CDC) to organize an effective response.
BARDA manages Project BioShield, which includes the procurement and advanced development of medical countermeasures for chemical, biological, radiological, and nuclear agents, as well as the advanced development and procurement of medical countermeasures for pandemic influenza and other emerging infectious diseases that fall outside the auspices of Project BioShield. In addition, BARDA manages the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) and is a key partner in implementing the PHEMCE strategies.
To learn more about requirements setting for medical countermeasure research and development click here.
The PHEMCE has taken a holistic, end-to-end approach to planning that considers multiple aspects of the medical countermeasures mission. The HHS PHEMCE Strategy for Chemical, Biological, Radiological, and Nuclear (CBRN) Threats establishes the goals and objectives that HHS will use to ensure that medical countermeasures are available for effective use against the highest priority CBRN threats facing the Nation. The HHS PHEMCE Implementation Plan for CBRN Threats is a prioritized plan with near-, mid-, and long-term goals for research, development, and acquisition of medical countermeasures.
The PHEMCE is led by the Enterprise Senior Council (ESC), which serves as the decision forum for MCM development policy and implementation. The ESC is chaired by ASPR and is comprised of Senior Leaders of the enterprise.